Eyepoint Pharmaceuticals, Inc. $EYPT Stock Position Boosted by California State Teachers Retirement System

Key Points

• California State Teachers Retirement System increased its Eyepoint Pharmaceuticals stake by 2,158.3% in the first quarter, acquiring 100,447 additional shares for a total of 105,101 shares. Institutional investors collectively own 99.41% of EYPT.
• Eyepoint shares opened at $13.48, compared with a 52-week range of $9.65 to $19.11. The company reported a quarterly loss of $1.09 per share, missing estimates, though revenue of $510,000 exceeded expectations.
• Analyst sentiment remains generally positive, with a “Moderate Buy” consensus and an average price target of $44.38; however, price targets range widely from $27 to $65, and Weiss Ratings maintains a sell rating.

California State Teachers Retirement System grew its stake in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 2,158.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 105,101 shares of the company's stock after buying an additional 100,447 shares during the quarter. California State Teachers Retirement System owned about 0.13% of Eyepoint Pharmaceuticals worth $1,355,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in EYPT. Rhumbline Advisers lifted its stake in Eyepoint Pharmaceuticals by 11.0% in the second quarter. Rhumbline Advisers now owns 96,280 shares of the company's stock valued at $906,000 after buying an additional 9,548 shares in the last quarter. American Century Companies Inc. increased its holdings in Eyepoint Pharmaceuticals by 57.8% in the 2nd quarter. American Century Companies Inc. now owns 67,612 shares of the company's stock worth $636,000 after purchasing an additional 24,752 shares in the last quarter. Invesco Ltd. raised its position in Eyepoint Pharmaceuticals by 199.8% during the 2nd quarter. Invesco Ltd. now owns 128,772 shares of the company's stock worth $1,212,000 after purchasing an additional 85,824 shares during the last quarter. Raymond James Financial Inc. lifted its holdings in Eyepoint Pharmaceuticals by 11.0% in the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company's stock valued at $112,000 after buying an additional 1,177 shares during the period. Finally, Adage Capital Partners GP L.L.C. grew its stake in Eyepoint Pharmaceuticals by 9.7% during the second quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company's stock worth $63,988,000 after purchasing an additional 600,000 shares during the period. 99.41% of the stock is currently owned by institutional investors.

Eyepoint Pharmaceuticals Price Performance

Shares of EYPT opened at $13.48 on Friday. The firm has a market cap of $1.16 billion, a P/E ratio of -3.60 and a beta of 1.76. Eyepoint Pharmaceuticals, Inc. has a 1 year low of $9.65 and a 1 year high of $19.11. The company has a 50 day simple moving average of $13.17 and a two-hundred day simple moving average of $13.70.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%.The company had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. On average, sell-side analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -3.46 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on EYPT. HC Wainwright lowered their price target on shares of Eyepoint Pharmaceuticals from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Chardan Capital restated a "buy" rating and set a $65.00 price target on shares of Eyepoint Pharmaceuticals in a research note on Friday, August 7th. Royal Bank Of Canada dropped their price target on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an "outperform" rating for the company in a research report on Thursday, May 7th. Stifel Nicolaus assumed coverage on Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They set a "buy" rating and a $40.00 price objective for the company. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Eyepoint Pharmaceuticals in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $44.38.

Eyepoint Pharmaceuticals Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source